VISION
177Lu-PSMA-617 in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
Patient / Population Intervention / Exposition Vergleich Endpunkt
In 831 patients with PSMA-positive mCRPC after androgen-receptor signalling inhibition and taxane chemotherapy, 177Lu-PSMA-617 + standard care improved radiographic PFS and overall survival compared with standard care alone.
N
831
Design
Open-label RCT
Endpunkt
rPFS and OS
Relevanz
2
ErgebnisrPFS HR 0.40; OS 15.3 vs 11.3 months (HR 0.62).
Sartor O, et al. N Engl J Med. 2021;385(12):1091-1103. 10.1056/NEJMoa2107322
Diskussion & Kritik
First radioligand therapy with an OS benefit in heavily pretreated mCRPC. PSMA PET–based patient selection is essential.